Results 221 to 230 of about 29,210 (297)

Chronic oral administration of ibrutinib prevents long-term memory deficits and reduces AD pathology and neuroinflammatory responses in a mouse model of AD. [PDF]

Mol Brain
Lee HJ, Kang S, Jeong YJ, Park JH, Hwang JW, Gu CH, Jung TM, Oh S, Jang JY, Hoe HS.   +9 more
europepmc   +1 more source

Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results. [PDF]

Blood Adv
Shadman M, Burke JM, Cultrera J, Yimer HA, Zafar SF, Misleh J, Rao SS, Farber CM, Cohen A, Yao H, Idoine A, An Q, Flinn IW, Sharman JP.   +13 more
europepmc   +1 more source

COOKIE-Pro: covalent inhibitor binding kinetics profiling on the proteome scale. [PDF]

Nat Commun
Lin H, Yang B, Ding L, Yang YY, Holt MV, Jung SY, Zhang B, Wang MC, Wang J.   +8 more
europepmc   +1 more source

In silico analysis of atrial fibrillation and hypertension mechanism of action secondary to ibrutinib/acalabrutinib in chronic lymphocytic leukemia. [PDF]

Sci Rep
Córdoba R, Bayés-Genís A, Muntañola A, Colomer D, Castro J, Leiva C, Álvarez E, Zatarain-Nicolas E.   +7 more
europepmc   +1 more source

“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia”

, 2017
Maurizio Cavallari, Maria Ciccone, Simonetta Falzoni, Francesco Cavazzini, Luca Formigaro, Francesco Di Virgilio, Antonella Rotola, Gian Matteo Rigolin, Antonio Cuneo   +8 more
openalex   +1 more source

Resistance Mutations in CLL: Genetic Mechanisms Shaping the Future of Targeted Therapy. [PDF]

Genes (Basel)
Sekeres S, Lamkin EN, Bravo E, Cool A, Taylor J.   +4 more
europepmc   +1 more source

The Role of Tumor Microenvironment and Targeted Therapy in Chronic Lymphocytic Leukemia. [PDF]

Curr Issues Mol Biol
Saleh K, Arbab A, Khalife N, Khoury R, Ibrahim R, Hachem MA, Khalil C, Bou Orm C, Sawan J, Lafarge G, Masri N, Tikriti Z, Chahine C, Le Cesne A.   +13 more
europepmc   +1 more source

Beyond Atrial Fibrillation and Heart Failure: Ibrutinib-induced Pericardial Effusion. [PDF]

J Community Hosp Intern Med Perspect
Singh A, Rucktuhl K, Panchal V, Ramadas P.   +3 more
europepmc   +1 more source

EUROCOVER-CLL: Reimbursement and accessibility of new treatments in relapsed/refractory chronic lymphocytic leukemia. [PDF]

Front Pharmacol
Monica M, Becirovic S, Bianchi-Manaila I, Duborija-Kovacevic N, Draganic P, Garouliene K, Hammerman A, Ispan F, Ivanova B, Männik A, Meresz G, Nazaryan L, Oleshchuk O, Savova A, Skoupa J, Stefanovic N, Tesar T, Kawalec P.   +17 more
europepmc   +1 more source

Faculty Opinions recommendation of Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

, 2017
Varsha Gandhi, Prithviraj Bose
openalex   +2 more sources